SBLENDORIO GLENN 4

What Happened

• Glenn Sblendorio, a director of Amicus Therapeutics (FOLD), disposed of company securities on 2026-04-27 in connection with the company’s acquisition by BioMarin Pharmaceutical Inc.
• He sold 142,564 shares of common stock (including 20,414 restricted stock units that vested at closing) at $14.50 per share for total cash proceeds of $2,067,178.
• In addition, multiple stock options were cancelled and converted into cash payments (reported as derivative disposals with no per‑share price shown). All options were fully vested and vested in full on consummation of the merger.

Key Details

• Transaction date: 2026-04-27 (reported on Form 4 filed 2026-04-27).
• Priced sale: 142,564 shares @ $14.50 = $2,067,178.
• Derivative actions: several option cancellations (cash-out) and vested RSU vesting — option cash payment equals ( $14.50 - option exercise price ) × number of option shares (per filing).
• Shares owned after transaction: not specified in the provided filing.
• Filing timeliness: reported on the same date as the transaction; no late filing indicated in the filing excerpt.

Context

• This was a disposition tied to a corporate event (the merger), not an open-market sale — common in M&A transactions where equity awards and outstanding shares are cashed out or converted.
• The option-related entries are not purchases or exercises that increase share ownership; they reflect cancellation and cash settlement of vested options.